Aelis Farma SA
Aelis Farma SA is a biopharmaceutical company focused on the development and commercialization of innovative therapies for oncology and autoimmune diseases.
Business. Aelis Farma SA is a pharmaceutical company operating within the Healthcare sector, specifically engaged in the development and sale of pharmaceutical products. The company is headquartered in France and is primarily listed on the Euronext Paris under the ticker symbol AELIS.PA. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Aelis Farma SA is a pharmaceutical company operating within the Healthcare sector, specifically engaged in the development and sale of pharmaceutical products. The company is headquartered in France and is primarily listed on the Euronext Paris under the ticker symbol AELIS.PA. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.
Aelis Farma has a fully diluted share count of 13,706,586 shares, with no difference between basic and diluted shares outstanding, indicating no dilution risk from stock options or convertible instruments. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
The company reported a loss per share of -0.39 EUR and revenue of 9,054,000 EUR in the latest period. These figures suggest a lack of profitability and limited revenue generation, which is below the typical performance of companies in the biotechnology and pharmaceuticals industry. The absence of valuation snapshot data further limits the ability to compare Aelis Farma's financial performance against industry benchmarks.
Aelis Farma's revenue is not segmented by geographic region or product line in the available data, making it difficult to assess the geographic or product concentration of its business. This lack of transparency could pose a risk to investors seeking to understand the company's exposure to different markets or therapeutic areas.
The company's growth trajectory is unclear, as no outlook data is available for the current or next fiscal year. The absence of revenue history beyond the latest reported period also limits the ability to assess historical growth trends.
The risk assessment indicates low dilution risk, but liquidity risk could not be evaluated due to missing balance-sheet data. No dilution sources were identified in the available documents, and no adjustments were applied to the valuation metrics.
No recent events, such as filings or transcripts, were identified in the available data to provide insight into the company's current operations or strategic direction.
- Aelis Farma has no difference between basic and diluted shares outstanding, indicating no dilution risk from stock options or convertible instruments.
- The company reported a loss per share of -0.39 EUR and revenue of 9,054,000 EUR in the latest period.
- Liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
- No recent events or outlook data are available to assess the company's growth trajectory or strategic direction.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue €0.00, −100,0% YoY; Operating income +19,9% YoY.
- ▍Revenue €0.00, −100,0% YoY
- ▍Operating income +19,9% YoY
- ▍Net income +13,7% YoY
- ▍Free cash flow +16,5% YoY
Revenue €2.7M, −70,4% YoY; Operating income −19,7% YoY.
- ▍Revenue €2.7M, −70,4% YoY
- ▍Operating income −19,7% YoY
- ▍Net income −46,8% YoY
- ▍Free cash flow −47,6% YoY
- ▍Net margin -278.4%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Aelis Farma SA Market data — financials · 2026-05-27
- Aelis Farma SA Market data — analyst estimates · 2026-05-27